{"id":3926,"date":"2021-07-01T12:43:00","date_gmt":"2021-07-01T10:43:00","guid":{"rendered":"https:\/\/sefiro.de\/?p=3926"},"modified":"2021-11-05T12:51:02","modified_gmt":"2021-11-05T11:51:02","slug":"europaeisches-arzneibuch-ph-eur-neues-allgemeines-kapitel-ueber-pyrrolizidinalkaloide","status":"publish","type":"post","link":"https:\/\/sefiro.de\/en\/2021\/07\/01\/europaeisches-arzneibuch-ph-eur-neues-allgemeines-kapitel-ueber-pyrrolizidinalkaloide\/","title":{"rendered":"Europ\u00e4isches Arzneibuch (Ph. Eur.): neues allgemeines Kapitel \u00fcber Pyrrolizidinalkaloide."},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"3926\" class=\"elementor elementor-3926\">\n\t\t\t\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-81aea75 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"81aea75\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-3454efba\" data-id=\"3454efba\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t\t\t<div class=\"elementor-element elementor-element-1809dbfb elementor-widget elementor-widget-text-editor\" data-id=\"1809dbfb\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<p><!-- wp:paragraph --><\/p><p>Das neue Kapitel 2.8.26 Pyrrolizidinalkaloide wird am 01.01.2022 implementiert. Es behandelt die Spurenanalyse von Pyrrolizidinalkaloiden (PAs) in pflanzlichen Drogen, Zubereitungen aus pflanzlichen Drogen und pflanzlichen Arzneimitteln. PAs werden \u00fcber Beimengungen an (Un)Kr\u00e4utern und Gr\u00e4sern in das pflanzliche Ausgangsmaterial, das f\u00fcr die Arzneimittelherstellung verwendet wird, eingetragen. Die akute Toxizit\u00e4t, Genotoxizit\u00e4t und das karzinogene Potential von PAs sind seit Jahrzehnten bekannt. Aufgrund ihrer hohen Komplexit\u00e4t und der enormen Strukturvielfalt sowie der verschiedenen Arzneimittel-Matrices, gestaltet sich die PA-Analytik sehr aufw\u00e4ndig. Gem\u00e4\u00df Ph. Eur. ist die Verwendung eines beliebigen Verfahrens, das aus Chromatographie gekoppelt mit MS\/MS oder hochaufl\u00f6sender MS besteht und die in diesem Kapitel festgelegen Validierungsanforderungen erf\u00fcllt, zul\u00e4ssig.<\/p><p><!-- \/wp:paragraph --><!-- wp:paragraph --><!-- \/wp:paragraph --><\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Das neue Kapitel 2.8.26 Pyrrolizidinalkaloide wird am 01.01.2022 implementiert. Es behandelt die Spurenanalyse von Pyrrolizidinalkaloiden (PAs) in pflanzlichen Drogen, Zubereitungen aus pflanzlichen Drogen und pflanzlichen Arzneimitteln. PAs werden \u00fcber Beimengungen an (Un)Kr\u00e4utern und Gr\u00e4sern in das pflanzliche Ausgangsmaterial, das f\u00fcr die Arzneimittelherstellung verwendet wird, eingetragen. Die akute Toxizit\u00e4t, Genotoxizit\u00e4t und das karzinogene Potential von PAs &hellip;<\/p>\n<p class=\"read-more\"> <a class=\"\" href=\"https:\/\/sefiro.de\/en\/2021\/07\/01\/europaeisches-arzneibuch-ph-eur-neues-allgemeines-kapitel-ueber-pyrrolizidinalkaloide\/\"> <span class=\"screen-reader-text\">Europ\u00e4isches Arzneibuch (Ph. Eur.): neues allgemeines Kapitel \u00fcber Pyrrolizidinalkaloide.<\/span> Read More &raquo;<\/a><\/p>","protected":false},"author":3,"featured_media":2547,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[104,107],"tags":[],"class_list":["post-3926","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-analytik-technik","category-news-gesetze-richtlinien-non-food"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v20.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Europ\u00e4isches Arzneibuch (Ph. Eur.): neues allgemeines Kapitel \u00fcber Pyrrolizidinalkaloide. &ndash; SEFIRO GROUP<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/sefiro.de\/en\/2021\/07\/01\/europaeisches-arzneibuch-ph-eur-neues-allgemeines-kapitel-ueber-pyrrolizidinalkaloide\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Europ\u00e4isches Arzneibuch (Ph. Eur.): neues allgemeines Kapitel \u00fcber Pyrrolizidinalkaloide. &ndash; SEFIRO GROUP\" \/>\n<meta property=\"og:description\" content=\"Das neue Kapitel 2.8.26 Pyrrolizidinalkaloide wird am 01.01.2022 implementiert. Es behandelt die Spurenanalyse von Pyrrolizidinalkaloiden (PAs) in pflanzlichen Drogen, Zubereitungen aus pflanzlichen Drogen und pflanzlichen Arzneimitteln. PAs werden \u00fcber Beimengungen an (Un)Kr\u00e4utern und Gr\u00e4sern in das pflanzliche Ausgangsmaterial, das f\u00fcr die Arzneimittelherstellung verwendet wird, eingetragen. Die akute Toxizit\u00e4t, Genotoxizit\u00e4t und das karzinogene Potential von PAs &hellip; Europ\u00e4isches Arzneibuch (Ph. Eur.): neues allgemeines Kapitel \u00fcber Pyrrolizidinalkaloide. Read More &raquo;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/sefiro.de\/en\/2021\/07\/01\/europaeisches-arzneibuch-ph-eur-neues-allgemeines-kapitel-ueber-pyrrolizidinalkaloide\/\" \/>\n<meta property=\"og:site_name\" content=\"SEFIRO GROUP\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-01T10:43:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-11-05T11:51:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/sefiro.de\/wp-content\/uploads\/2021\/07\/Analytik-und-Technik.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1065\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Julia Rau\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Julia Rau\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/sefiro.de\/en\/2021\/07\/01\/europaeisches-arzneibuch-ph-eur-neues-allgemeines-kapitel-ueber-pyrrolizidinalkaloide\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/sefiro.de\/en\/2021\/07\/01\/europaeisches-arzneibuch-ph-eur-neues-allgemeines-kapitel-ueber-pyrrolizidinalkaloide\/\"},\"author\":{\"name\":\"Julia Rau\",\"@id\":\"https:\/\/sefiro.de\/#\/schema\/person\/8fae18c4eb743ab18f99d206493eb009\"},\"headline\":\"Europ\u00e4isches Arzneibuch (Ph. Eur.): neues allgemeines Kapitel \u00fcber Pyrrolizidinalkaloide.\",\"datePublished\":\"2021-07-01T10:43:00+00:00\",\"dateModified\":\"2021-11-05T11:51:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/sefiro.de\/en\/2021\/07\/01\/europaeisches-arzneibuch-ph-eur-neues-allgemeines-kapitel-ueber-pyrrolizidinalkaloide\/\"},\"wordCount\":125,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/sefiro.de\/#organization\"},\"articleSection\":[\"Analytik &amp; Technik\",\"Gesetze &amp; Richtlinien (Non-Food)\"],\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/sefiro.de\/en\/2021\/07\/01\/europaeisches-arzneibuch-ph-eur-neues-allgemeines-kapitel-ueber-pyrrolizidinalkaloide\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/sefiro.de\/en\/2021\/07\/01\/europaeisches-arzneibuch-ph-eur-neues-allgemeines-kapitel-ueber-pyrrolizidinalkaloide\/\",\"url\":\"https:\/\/sefiro.de\/en\/2021\/07\/01\/europaeisches-arzneibuch-ph-eur-neues-allgemeines-kapitel-ueber-pyrrolizidinalkaloide\/\",\"name\":\"Europ\u00e4isches Arzneibuch (Ph. Eur.): neues allgemeines Kapitel \u00fcber Pyrrolizidinalkaloide. &ndash; SEFIRO GROUP\",\"isPartOf\":{\"@id\":\"https:\/\/sefiro.de\/#website\"},\"datePublished\":\"2021-07-01T10:43:00+00:00\",\"dateModified\":\"2021-11-05T11:51:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/sefiro.de\/en\/2021\/07\/01\/europaeisches-arzneibuch-ph-eur-neues-allgemeines-kapitel-ueber-pyrrolizidinalkaloide\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/sefiro.de\/en\/2021\/07\/01\/europaeisches-arzneibuch-ph-eur-neues-allgemeines-kapitel-ueber-pyrrolizidinalkaloide\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/sefiro.de\/en\/2021\/07\/01\/europaeisches-arzneibuch-ph-eur-neues-allgemeines-kapitel-ueber-pyrrolizidinalkaloide\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/sefiro.de\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Europ\u00e4isches Arzneibuch (Ph. Eur.): neues allgemeines Kapitel \u00fcber Pyrrolizidinalkaloide.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/sefiro.de\/#website\",\"url\":\"https:\/\/sefiro.de\/\",\"name\":\"SEFIRO GROUP\",\"description\":\"Qualit\u00e4t und Sicherheit\",\"publisher\":{\"@id\":\"https:\/\/sefiro.de\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/sefiro.de\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/sefiro.de\/#organization\",\"name\":\"SEFIRO GROUP\",\"url\":\"https:\/\/sefiro.de\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/sefiro.de\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/sefiro.de\/wp-content\/uploads\/2021\/04\/SEFIRO_Logo_Group_4C_Final_21-12_WEB.jpg\",\"contentUrl\":\"https:\/\/sefiro.de\/wp-content\/uploads\/2021\/04\/SEFIRO_Logo_Group_4C_Final_21-12_WEB.jpg\",\"width\":1012,\"height\":454,\"caption\":\"SEFIRO GROUP\"},\"image\":{\"@id\":\"https:\/\/sefiro.de\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/sefiro.de\/#\/schema\/person\/8fae18c4eb743ab18f99d206493eb009\",\"name\":\"Julia Rau\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/sefiro.de\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/07a2e132bd3c82222edbec571358df131f0a750ff3b5a6c1963d0a05db716d0e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/07a2e132bd3c82222edbec571358df131f0a750ff3b5a6c1963d0a05db716d0e?s=96&d=mm&r=g\",\"caption\":\"Julia Rau\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Europ\u00e4isches Arzneibuch (Ph. Eur.): neues allgemeines Kapitel \u00fcber Pyrrolizidinalkaloide. &ndash; SEFIRO GROUP","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/sefiro.de\/en\/2021\/07\/01\/europaeisches-arzneibuch-ph-eur-neues-allgemeines-kapitel-ueber-pyrrolizidinalkaloide\/","og_locale":"en_GB","og_type":"article","og_title":"Europ\u00e4isches Arzneibuch (Ph. Eur.): neues allgemeines Kapitel \u00fcber Pyrrolizidinalkaloide. &ndash; SEFIRO GROUP","og_description":"Das neue Kapitel 2.8.26 Pyrrolizidinalkaloide wird am 01.01.2022 implementiert. Es behandelt die Spurenanalyse von Pyrrolizidinalkaloiden (PAs) in pflanzlichen Drogen, Zubereitungen aus pflanzlichen Drogen und pflanzlichen Arzneimitteln. PAs werden \u00fcber Beimengungen an (Un)Kr\u00e4utern und Gr\u00e4sern in das pflanzliche Ausgangsmaterial, das f\u00fcr die Arzneimittelherstellung verwendet wird, eingetragen. Die akute Toxizit\u00e4t, Genotoxizit\u00e4t und das karzinogene Potential von PAs &hellip; Europ\u00e4isches Arzneibuch (Ph. Eur.): neues allgemeines Kapitel \u00fcber Pyrrolizidinalkaloide. Read More &raquo;","og_url":"https:\/\/sefiro.de\/en\/2021\/07\/01\/europaeisches-arzneibuch-ph-eur-neues-allgemeines-kapitel-ueber-pyrrolizidinalkaloide\/","og_site_name":"SEFIRO GROUP","article_published_time":"2021-07-01T10:43:00+00:00","article_modified_time":"2021-11-05T11:51:02+00:00","og_image":[{"width":1920,"height":1065,"url":"https:\/\/sefiro.de\/wp-content\/uploads\/2021\/07\/Analytik-und-Technik.jpg","type":"image\/jpeg"}],"author":"Julia Rau","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Julia Rau","Estimated reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/sefiro.de\/en\/2021\/07\/01\/europaeisches-arzneibuch-ph-eur-neues-allgemeines-kapitel-ueber-pyrrolizidinalkaloide\/#article","isPartOf":{"@id":"https:\/\/sefiro.de\/en\/2021\/07\/01\/europaeisches-arzneibuch-ph-eur-neues-allgemeines-kapitel-ueber-pyrrolizidinalkaloide\/"},"author":{"name":"Julia Rau","@id":"https:\/\/sefiro.de\/#\/schema\/person\/8fae18c4eb743ab18f99d206493eb009"},"headline":"Europ\u00e4isches Arzneibuch (Ph. Eur.): neues allgemeines Kapitel \u00fcber Pyrrolizidinalkaloide.","datePublished":"2021-07-01T10:43:00+00:00","dateModified":"2021-11-05T11:51:02+00:00","mainEntityOfPage":{"@id":"https:\/\/sefiro.de\/en\/2021\/07\/01\/europaeisches-arzneibuch-ph-eur-neues-allgemeines-kapitel-ueber-pyrrolizidinalkaloide\/"},"wordCount":125,"commentCount":0,"publisher":{"@id":"https:\/\/sefiro.de\/#organization"},"articleSection":["Analytik &amp; Technik","Gesetze &amp; Richtlinien (Non-Food)"],"inLanguage":"en-GB","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/sefiro.de\/en\/2021\/07\/01\/europaeisches-arzneibuch-ph-eur-neues-allgemeines-kapitel-ueber-pyrrolizidinalkaloide\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/sefiro.de\/en\/2021\/07\/01\/europaeisches-arzneibuch-ph-eur-neues-allgemeines-kapitel-ueber-pyrrolizidinalkaloide\/","url":"https:\/\/sefiro.de\/en\/2021\/07\/01\/europaeisches-arzneibuch-ph-eur-neues-allgemeines-kapitel-ueber-pyrrolizidinalkaloide\/","name":"Europ\u00e4isches Arzneibuch (Ph. Eur.): neues allgemeines Kapitel \u00fcber Pyrrolizidinalkaloide. &ndash; SEFIRO GROUP","isPartOf":{"@id":"https:\/\/sefiro.de\/#website"},"datePublished":"2021-07-01T10:43:00+00:00","dateModified":"2021-11-05T11:51:02+00:00","breadcrumb":{"@id":"https:\/\/sefiro.de\/en\/2021\/07\/01\/europaeisches-arzneibuch-ph-eur-neues-allgemeines-kapitel-ueber-pyrrolizidinalkaloide\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/sefiro.de\/en\/2021\/07\/01\/europaeisches-arzneibuch-ph-eur-neues-allgemeines-kapitel-ueber-pyrrolizidinalkaloide\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/sefiro.de\/en\/2021\/07\/01\/europaeisches-arzneibuch-ph-eur-neues-allgemeines-kapitel-ueber-pyrrolizidinalkaloide\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/sefiro.de\/"},{"@type":"ListItem","position":2,"name":"Europ\u00e4isches Arzneibuch (Ph. Eur.): neues allgemeines Kapitel \u00fcber Pyrrolizidinalkaloide."}]},{"@type":"WebSite","@id":"https:\/\/sefiro.de\/#website","url":"https:\/\/sefiro.de\/","name":"SEFIRO GROUP","description":"Qualit\u00e4t und Sicherheit","publisher":{"@id":"https:\/\/sefiro.de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/sefiro.de\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/sefiro.de\/#organization","name":"SEFIRO GROUP","url":"https:\/\/sefiro.de\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/sefiro.de\/#\/schema\/logo\/image\/","url":"https:\/\/sefiro.de\/wp-content\/uploads\/2021\/04\/SEFIRO_Logo_Group_4C_Final_21-12_WEB.jpg","contentUrl":"https:\/\/sefiro.de\/wp-content\/uploads\/2021\/04\/SEFIRO_Logo_Group_4C_Final_21-12_WEB.jpg","width":1012,"height":454,"caption":"SEFIRO GROUP"},"image":{"@id":"https:\/\/sefiro.de\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/sefiro.de\/#\/schema\/person\/8fae18c4eb743ab18f99d206493eb009","name":"Julia Rau","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/sefiro.de\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/07a2e132bd3c82222edbec571358df131f0a750ff3b5a6c1963d0a05db716d0e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/07a2e132bd3c82222edbec571358df131f0a750ff3b5a6c1963d0a05db716d0e?s=96&d=mm&r=g","caption":"Julia Rau"}}]}},"jetpack_featured_media_url":"https:\/\/sefiro.de\/wp-content\/uploads\/2021\/07\/Analytik-und-Technik.jpg","_links":{"self":[{"href":"https:\/\/sefiro.de\/en\/wp-json\/wp\/v2\/posts\/3926","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sefiro.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sefiro.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sefiro.de\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/sefiro.de\/en\/wp-json\/wp\/v2\/comments?post=3926"}],"version-history":[{"count":4,"href":"https:\/\/sefiro.de\/en\/wp-json\/wp\/v2\/posts\/3926\/revisions"}],"predecessor-version":[{"id":3931,"href":"https:\/\/sefiro.de\/en\/wp-json\/wp\/v2\/posts\/3926\/revisions\/3931"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sefiro.de\/en\/wp-json\/wp\/v2\/media\/2547"}],"wp:attachment":[{"href":"https:\/\/sefiro.de\/en\/wp-json\/wp\/v2\/media?parent=3926"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sefiro.de\/en\/wp-json\/wp\/v2\/categories?post=3926"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sefiro.de\/en\/wp-json\/wp\/v2\/tags?post=3926"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}